Enobosarm

Phase 2Small molecule

VVeru Inc.

Enobosarm is one of 13 small molecule programs targeting Obesity & Overweight. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obesity & OverweightActive, not recruiting

Obesity & OverweightPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Obesity & Overweight

#DrugCompanyPhaseTrials

Mazdutide

Eli Lilly

Phase 3

1 2

Ozempic

Novo Nordisk

Phase 2

2 3

AZD6234

AstraZeneca

Phase 2

1 4

AZD9550

AstraZeneca

Phase 2

1 5

Crestor

AstraZeneca

Preclinical

1 6

Semagludtide

Novo Nordisk

Phase 2

1 7

LUM-201

LLumos Pharma

Phase 2

1 8

Enobosarm

VVeru Inc.

Phase 2

1 9

CX11

CCorxel Pharmaceuticals

Phase 1

1 10

Incretin-Based Treatment

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Obesity & Overweight

NCT07446998

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02971761·18 enrolled

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated·VVeru Inc.·Phase 3·NCT04869943·52 enrolled

Menopausal Women1 trial

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

Completed·UUnknown Sponsor·Phase 1·NCT03264651·9 enrolled

Chronic1 trial

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Completed·VVeru Inc.·Phase 2·NCT06282458·168 enrolled

Obesity & Overweight1 trial

PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction

Active, not recruiting·VVeru Inc.·Phase 2·NCT07446998·239 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Enobosarm. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enobosarm compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enobosarm. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veru Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVeru Inc.

Enobosarm

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Breast Cancer2 trials

Menopausal Women1 trial

Chronic1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News